Business Wire

Upper Egypt Local Development Program Selects Esri Software for Data-Driven Governance

2.9.2021 16:42:00 EEST | Business Wire | Press release

Share

When the United Nations adopted the Sustainable Development Goals (SDGs) as a global call to action to achieve a more sustainable future for all by 2030, many countries committed to the cause. Egypt, which launched its strategy in 2016, met the obstacle of geographic disparities due to the need for development in the upper region of the nation. To address this challenge, the Egyptian Ministry of Local Development and the World Bank launched the Upper Egypt Local Development Program (UELDP) a year later.

One vital step toward improving development in Upper Egypt—and part of UELDP—includes establishing a GIS infrastructure in the region. To achieve this, UELDP chose location intelligence world leader Esri to provide the region's new GIS unit with all the required hardware, software, data, and applications necessary for managing complex geospatial data.

"This is a strategically important project, which will play a vital role in driving sustainable, impactful urban planning and development to support communities in Upper Egypt," said Dr. Mohamed Misbah, director for the Middle East and Africa region at Khatib & Alami (K&A), an Esri Platinum partner.

The project will leverage a unified geodatabase and a map viewer to explore geostatistical information and generate reports, graphics, and thematic maps. It will also employ mobile applications for data collection that allow government staff to access data from the field. These services, in addition to operational dashboards, will provide a holistic view for policy makers.

Laying the foundation for asset management systems at the governorate (jurisdictional) level, Esri’s ArcGIS software helps integrate them with databases in relevant ministries and central government agencies. This enables these organizations to comprehensively display vast amounts of statistical and spatial information to support long-term planning and execution in line with UELDP's vision and future goals.

Further strengthening the governorates' capacities, GIS will enable local development data to be georeferenced to support decision-making. The implementation of this system was awarded to Esri partners ProSyLab and K&A.

"ProSyLab, as an Esri partner, adds to its achievements [by] participating in this national project," said Mahmoud Moursi, ProSyLab chairman. "The project aims to help the public sector, represented by the UELDP, in establishing a GIS infrastructure, which promotes the concept of data sharing, facilitating the decision-making process, and building capacity."

UELDP aims to localize sustainable development, create new job opportunities, improve the economy, and strengthen government capacity for quality infrastructure and service delivery in select governorates in Upper Egypt. It was piloted in the Qena and Sohag Governorates to address existing development gaps and has met with success, leading to national policy reforms, and even inspiring a scaled-up version of the program for Egypt's 2019 Decent Life initiative.

To learn more about how UELDP is using technology to enhance public services, visit ueldp.gov.eg.

About K&A

Khatib & Alami (K&A) is an international multidisciplinary consultancy composed of architects, engineers, planners, technologists and other project specialists. With 6,000 people in more than 30 locations, K&A has vast experience working at the forefront of fast changing urban environments, with a deep understanding of delivering complex major projects within agreed time frames and budgets.

Since launching its Geospatial Systems Integration division in 1988, K&A has become one of the leaders in its field, with a 200-strong team of GIS experts. K&A helps government and private sector clients make sense of the vast quantities of information and data available to them, providing insight, enabling better decision-making, creating efficiencies, and improving customer experiences. As an Esri Platinum partner, K&A continuously provides innovative smart solutions that address business challenges and exceed customers' expectations. For more information visit www.khatibalami.com.

About ProSyLab

ProSyLab is an information and communications technology company started in 1994. Since then, ProSyLab solutions have supported various customers in both the private and public sectors across Egypt as well as the Middle East.

ProSyLab (PSL) has a unique spirit and expertise which converts challenges into new success stories. With a portfolio of five companies in different market segments, ProSyLab has been supporting private sector and governmental enterprises across Egypt as well as the Middle East. PSL's innovative ideas and solutions are not merely our philosophy, but also our everyday reality. We remain dedicated to leading the world into a more prosperous and progressive future: by enhancing the world to become more diverse, more tolerant, and more just.

About Esri

Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.

Copyright © 2021 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jo Ann Pruchniewski
Public Relations, Esri
Mobile: 301-693-2643
Email: jpruchniewski@esri.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 14:42:00 EEST | Press release

Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429263104/en/ • Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn • Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions • Transaction expected to close in

Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 14:00:00 EEST | Press release

Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S. Marines. The Next Generation EW prototype is centered on the C5ISR Modular Open Suite of S

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 14:00:00 EEST | Press release

Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means our partners can choose the networks that best fit their needs, while relying on Visa to provide

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior

European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye